Media stories about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Zimmer Biomet earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.1826809880613 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer (feeds.benzinga.com)
- Zimmer Biomet Touts First Surgery of New Tibia (insideindianabusiness.com)
- Zimmer Biomet wins FDA nod, launches Persona trabecular metal tibia (massdevice.com)
- Zimmer Biomet Holdings Inc.: Zimmer Biomet Announces FDA Clearance and First Surgical Case of the Persona® Trabecular Metal™ Tibia (twst.com)
- FY2019 EPS Estimates for Zimmer Biomet (ZBH) Decreased by Leerink Swann (americanbankingnews.com)
Shares of ZBH traded up $1.58 during trading hours on Tuesday, hitting $108.82. 1,144,224 shares of the company were exchanged, compared to its average volume of 1,281,248. The firm has a market cap of $21,446.22, a P/E ratio of 13.55, a price-to-earnings-growth ratio of 1.84 and a beta of 1.17. Zimmer Biomet has a fifty-two week low of $104.28 and a fifty-two week high of $133.49. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.81 and a current ratio of 1.50.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 11.96%.
A number of equities research analysts recently weighed in on ZBH shares. Canaccord Genuity restated a “hold” rating and issued a $125.00 price target on shares of Zimmer Biomet in a research note on Tuesday, December 19th. Goldman Sachs upgraded Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target on the stock in a research note on Tuesday, December 19th. Citigroup dropped their price target on Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 27th. ValuEngine upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Finally, Oppenheimer reiterated a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet presently has a consensus rating of “Buy” and a consensus target price of $138.80.
In related news, insider Bryan C. Hanson bought 25,077 shares of Zimmer Biomet stock in a transaction dated Tuesday, February 20th. The shares were bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Chad F. Phipps sold 20,826 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The disclosure for this sale can be found here. Corporate insiders own 0.71% of the company’s stock.
WARNING: “Zimmer Biomet (ZBH) Receiving Somewhat Favorable Press Coverage, Study Shows” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2018/04/17/zimmer-biomet-zbh-receiving-somewhat-favorable-press-coverage-study-shows.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.